ストックスクリーナーアプリを入手
6.08
5.00%
-0.32
前日終値:
$6.40
開ける：
$6.44
24時間の取引高:
1.16M
Relative Volume:
1.09
時価総額：
$473.69M
収益：
$14.79M
当期純損益:
$-102.44M
株価収益率:
-2.00
EPS:
-3.04
ネットキャッシュフロー:
$-91.73M
1週間 パフォーマンス:
-2.41%
1か月 パフォーマンス:
+16.03%
6か月 パフォーマンス:
+0.66%
1年 パフォーマンス:
+72.24%
1日の値動き範囲:
$6.01
$6.45
1週間の範囲:
$5.71
$7.33
52週間の値動き範囲:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
名前
Solid Biosciences Inc
セクター
電話
617-337-4680
住所
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.08 | 498.63M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-04 | 開始されました | Needham | Buy |
| 2025-06-26 | 開始されました | Citigroup | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-13 | 開始されました | Wedbush | Outperform |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-15 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-06-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 再開されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | William Blair | Outperform |
| 2024-03-15 | 開始されました | Citigroup | Buy |
| 2024-03-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-07-12 | 開始されました | Piper Sandler | Neutral |
| 2021-05-27 | 開始されました | Jefferies | Buy |
| 2021-03-16 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2021-01-08 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 開始されました | Evercore ISI | Outperform |
| 2019-08-29 | ダウングレード | Citigroup | Neutral → Sell |
| 2019-08-19 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | ダウングレード | Goldman | Neutral → Sell |
| 2019-02-08 | アップグレード | Citigroup | Sell → Neutral |
| 2019-02-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 開始されました | Citigroup | Sell |
| 2018-09-06 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Solid Biosciences Inc (SLDB) 最新ニュース
Solid Biosciences (SLDB) Gets a Buy from Wedbush - The Globe and Mail
Citizens reiterates Market Outperform rating on Solid Biosciences stock By Investing.com - Investing.com Nigeria
Citizens reiterates Market Outperform rating on Solid Biosciences stock - Investing.com
Solid Biosciences advances Duchenne treatment with FDA alignment By Investing.com - Investing.com South Africa
Solid Biosciences: Positive FDA Meeting SGT-003 Sets Up Next Milestones (NASDAQ:SLDB) - Seeking Alpha
Needham Reiterates Buy Rating for Solid Biosciences (SLDB) at $1 - GuruFocus
Needham & Company LLC Reaffirms Buy Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (SLDB) Gains FDA Alignment for Duchenne Trial - GuruFocus
Solid Biosciences Receives Positive FDA Feedback - Intellectia AI
Solid Biosciences To Dose First Patient In IMPACT DUCHENNE Phase 3 Trial In Q1'26 - Nasdaq
Solid Biosciences stock rises after FDA alignment on Phase 3 trial design - Investing.com Australia
Solid Biosciences (SLDB) Advances Duchenne Therapy with FDA Support - GuruFocus
Solid Biosciences Aligns With FDA on Phase 3 Trial Design for Duchenne Muscular Dystrophy Gene Therapy - marketscreener.com
Solid Bio, FDA agree on trial for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences advances Duchenne treatment with FDA alignment - Investing.com
Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy - The Manila Times
Merger Talk: Why is Solid Biosciences Inc. stock going upWeekly Stock Analysis & Safe Entry Point Identification - baoquankhu1.vn
Death Cross: What are Solid Biosciences Incs earnings expectations2025 Trade Ideas & Fast Entry Momentum Alerts - baoquankhu1.vn
Solid Biosciences CTO Herzich sells $70k in SLDB stock By Investing.com - Investing.com Canada
Solid Biosciences chief regulatory officer sells $79,544 in SLDB By Investing.com - Investing.com UK
Solid Biosciences CMO Brooks sells $81k in shares By Investing.com - Investing.com South Africa
Solid Biosciences chief regulatory officer sells $79,544 in SLDB - Investing.com India
Solid Biosciences CTO Herzich sells $70k in SLDB stock - Investing.com
Solid Biosciences CEO Cumbo sells $315,092 in stock By Investing.com - Investing.com Canada
Ilan Ganot, Solid Biosciences director, sells $46k in shares By Investing.com - Investing.com UK
Solid Biosciences CEO Cumbo sells $315,092 in stock - Investing.com
Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 14,783 Shares - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells 48,913 Shares of Stock - MarketBeat
Solid Biosciences Flies Ahead of Summit - Baystreet.ca
Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Solid Biosciences Inc. (NASDAQ:SLDB) Sees Large Decline in Short Interest - MarketBeat
Solid Biosciences COO Howton sells $243k in shares By Investing.com - Investing.com UK
Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 26,837 Shares - MarketBeat
Alexander Cumbo Sells 80,258 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Gabriel Brooks Sells 28,335 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences (NASDAQ:SLDB) COO Sells $243,245.24 in Stock - MarketBeat
Paul Herzich Sells 26,250 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences CFO sells $172k in shares By Investing.com - Investing.com UK
Solid Biosciences CFO sells $172k in shares - Investing.com
Solid Biosciences COO Howton sells $243k in shares - Investing.com
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
EPS Watch: Can Vail Resorts Inc sustain earnings growth2025 Technical Patterns & High Win Rate Trade Alerts - baoquankhu1.vn
Solid Biosciences Inc (SLDB) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):